A
Aseem Anand
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 63
Citations - 4531
Aseem Anand is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Prostate cancer & Circulating tumor cell. The author has an hindex of 23, co-authored 59 publications receiving 4029 citations. Previous affiliations of Aseem Anand include Lund University & Cornell University.
Papers
More filters
Journal ArticleDOI
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
Howard I. Scher,Tomasz M. Beer,Celestia S. Higano,Aseem Anand,Mary-Ellen Taplin,Eleni Efstathiou,Dana E. Rathkopf,Julia Shelkey,Evan Y. Yu,Joshi J. Alumkal,David T. Hung,Mohammad Hirmand,Lynn Seely,Michael J. Morris,Daniel C. Danila,John L. Humm,Steve Larson,Martin Fleisher,Charles L. Sawyers,Charles L. Sawyers +19 more
TL;DR: The results of this phase 1-2 trial validate in man preclinical studies implicating sustained androgen-receptor signalling as a driver in this disease.
Journal ArticleDOI
Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer
Daniel C. Danila,Glenn Heller,Gretchen A. Gignac,Rita Gonzalez-Espinoza,Aseem Anand,Erika Tanaka,Hans Lilja,Lawrence H. Schwartz,Steven M. Larson,Martin Fleisher,Howard I. Scher +10 more
TL;DR: Baseline CTC number was strongly associated with survival, without a threshold effect, which increased further when baseline prostate-specific antigen and albumin were included, and was predictive of survival, with no threshold effect.
Journal ArticleDOI
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.
Pedram Razavi,Bob T. Li,David N Brown,Byoungsok Jung,Earl Hubbell,Ronglai Shen,Wassim Abida,Krishna Juluru,Ino de Bruijn,Chenlu Hou,Oliver Venn,Raymond S. Lim,Aseem Anand,Tara Maddala,Sante Gnerre,Ravi Vijaya Satya,Qinwen Liu,Ling Shen,Nicholas Eattock,Jeanne Yue,Alexander W. Blocker,Mark Lee,Amy J. Sehnert,Hui Xu,Megan P. Hall,Angie Santiago-Zayas,William Novotny,James M. Isbell,Valerie W. Rusch,George Plitas,Alexandra S. Heerdt,Marc Ladanyi,David M. Hyman,David R. Jones,Monica Morrow,Gregory J. Riely,Howard I. Scher,Charles M. Rudin,Mark E. Robson,Luis A. Diaz,David B. Solit,Alex Aravanis,Jorge S. Reis-Filho +42 more
TL;DR: Ultra-sensitive cell-free DNA (cfDNA) sequencing uncovers clonal hematopoiesis as a major source of somatic cfDNA variants in healthy individuals and patients with cancer, and underscores the importance of matched white blood cell DNA sequencing in liquid biopsy procedures.
Journal ArticleDOI
Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
Daniel C. Danila,Michael J. Morris,Johann S. de Bono,Charles J. Ryan,Samuel R. Denmeade,Matthew R. Smith,Mary-Ellen Taplin,Glenn J. Bubley,Thian Kheoh,Christopher M. Haqq,Arturo Molina,Aseem Anand,Michael Koscuiszka,Steve Larson,Lawrence H. Schwartz,Martin Fleisher,Howard I. Scher +16 more
TL;DR: This trial evaluated the efficacy and safety of AA in combination with prednisone to reduce the symptoms of secondary hyperaldosteronism that can occur with AA monotherapy, with encouraging antitumor activity in heavily pretreated CRPC patients.
Journal ArticleDOI
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer
David R. Shaffer,Margaret Leversha,Daniel C. Danila,Oscar Lin,Rita Gonzalez-Espinoza,Bin Gu,Aseem Anand,Katherine Smith,Peter Maslak,Gerald V. Doyle,Leon W.M.M. Terstappen,Hans Lilja,Glenn Heller,Martin Fleisher,Howard I. Scher +14 more
TL;DR: The analysis of cancer-related alterations at the DNA and protein level from CTCs is feasible in a hospital-based clinical laboratory and the alterations observed in EGFR and AR suggest that the methodology may have a role in clinical decision making.